Obesity-associated changes in molecular biology of primary breast cancer.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
21 07 2023
Historique:
received: 24 01 2023
accepted: 06 07 2023
medline: 24 7 2023
pubmed: 22 7 2023
entrez: 21 7 2023
Statut: epublish

Résumé

Obesity is associated with an increased risk of developing breast cancer (BC) and worse prognosis in BC patients, yet its impact on BC biology remains understudied in humans. This study investigates how the biology of untreated primary BC differs according to patients' body mass index (BMI) using data from >2,000 patients. We identify several genomic alterations that are differentially prevalent in overweight or obese patients compared to lean patients. We report evidence supporting an ageing accelerating effect of obesity at the genetic level. We show that BMI-associated differences in bulk transcriptomic profile are subtle, while single cell profiling allows detection of more pronounced changes in different cell compartments. These analyses further reveal an elevated and unresolved inflammation of the BC tumor microenvironment associated with obesity, with distinct characteristics contingent on the estrogen receptor status. Collectively, our analyses imply that obesity is associated with an inflammaging-like phenotype. We conclude that patient adiposity may play a significant role in the heterogeneity of BC and should be considered for BC treatment tailoring.

Identifiants

pubmed: 37479706
doi: 10.1038/s41467-023-39996-z
pii: 10.1038/s41467-023-39996-z
pmc: PMC10361985
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

4418

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Cancer Research UK
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 077012/Z/05/Z
Pays : United Kingdom

Informations de copyright

© 2023. The Author(s).

Références

Clin Transl Oncol. 2020 Nov;22(11):1952-1962
pubmed: 32306242
Nat Genet. 2016 Feb;48(2):104-6
pubmed: 26813759
Oncogene. 2013 Feb 28;32(9):1073-81
pubmed: 22580612
Nat Med. 2021 May;27(5):820-832
pubmed: 33958794
Radiother Oncol. 2011 Aug;100(2):236-40
pubmed: 21296441
Curr Oncol Rep. 2018 Apr 11;20(6):47
pubmed: 29644507
Oncol Rep. 2011 Feb;25(2):477-83
pubmed: 21165572
Int J Mol Sci. 2013 Sep 04;14(9):18148-80
pubmed: 24009024
Nat Biotechnol. 2019 Jul;37(7):773-782
pubmed: 31061481
Clin Cancer Res. 2022 Apr 1;28(7):1258-1267
pubmed: 35046057
J Clin Oncol. 2010 Jul 20;28(21):3411-5
pubmed: 20547990
Plast Reconstr Surg. 2013 Oct;132(4):750-761
pubmed: 24076667
J Clin Oncol. 2016 Jun 1;34(16):1872-81
pubmed: 26926684
J Physiol. 2016 Jun 15;594(12):3187-207
pubmed: 26926488
Oncol Lett. 2018 Jul;16(1):41-47
pubmed: 29930712
N Engl J Med. 2019 May 16;380(20):1929-1940
pubmed: 31091374
Cancer Biol Ther. 2008 Dec;7(12):2034-8
pubmed: 19106633
J Pathol. 2015 Aug;236(4):457-66
pubmed: 25850943
Breast Cancer Res Treat. 2010 Oct;123(3):627-35
pubmed: 20571870
Mol Cell Endocrinol. 2005 Jan 14;229(1-2):161-73
pubmed: 15607540
Bioinformatics. 2022 Jan 12;38(3):844-845
pubmed: 34664620
Obes Rev. 2009 Nov;10(6):610-6
pubmed: 19527447
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Nat Rev Endocrinol. 2019 Mar;15(3):139-154
pubmed: 30459447
Breast Cancer Res. 2015 Aug 19;17:112
pubmed: 26286584
Elife. 2021 Jan 25;10:
pubmed: 33491650
J Clin Oncol. 2016 Dec 10;34(35):4270-4276
pubmed: 27903155
Oncologist. 2016 Apr;21(4):404-17
pubmed: 26865587
Gene. 2020 Feb 5;726:144223
pubmed: 31669645
JCO Precis Oncol. 2017 Jul;2017:
pubmed: 28890946
Oncotarget. 2015 Sep 22;6(28):24627-35
pubmed: 26384365
Ther Adv Med Oncol. 2019 Jul 16;11:1758835919864247
pubmed: 31360238
Front Oncol. 2021 Mar 02;11:628653
pubmed: 33738261
BMC Obes. 2016 Apr 29;3:22
pubmed: 27148454
Proc Natl Acad Sci U S A. 2021 Apr 27;118(17):
pubmed: 33875595
Nature. 2016 May 02;534(7605):47-54
pubmed: 27135926
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Lancet Oncol. 2022 Nov;23(11):1367-1377
pubmed: 36183733
Front Immunol. 2012 Jan 12;2:98
pubmed: 22566887
N Engl J Med. 2016 Aug 25;375(8):717-29
pubmed: 27557300
Nutr Cancer. 2014;66(8):1371-85
pubmed: 25356800
Commun Biol. 2020 Jul 27;3(1):397
pubmed: 32719399
J Clin Oncol. 2020 Sep 1;38(25):2883-2891
pubmed: 32614702
Breast Cancer Res Treat. 2012 Oct;135(3):725-35
pubmed: 22910931
Ann Oncol. 2019 Mar 1;30(3):365-373
pubmed: 30715161
Nat Rev Endocrinol. 2020 Nov;16(11):615-616
pubmed: 32873971
Nat Commun. 2021 Feb 17;12(1):1088
pubmed: 33597522
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Biochim Biophys Acta Gene Regul Mech. 2020 Jun;1863(6):194445
pubmed: 31654804
Nat Genet. 2003 Jul;34(3):267-73
pubmed: 12808457
Breast Cancer Res. 2012 May 14;14(3):R76
pubmed: 22583394
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Clin Cancer Res. 2013 Nov 15;19(22):6074-83
pubmed: 23958744
Nat Rev Cancer. 2003 Nov;3(11):859-68
pubmed: 14668816
Sci Rep. 2021 Jan 18;11(1):1679
pubmed: 33462316
J Clin Oncol. 2016 Dec 10;34(35):4277-4283
pubmed: 27903152
Breast Cancer Res. 2019 Dec 26;21(1):151
pubmed: 31878981
Cancer Epidemiol Biomarkers Prev. 2011 Mar;20(3):454-63
pubmed: 21364029
Front Oncol. 2021 Mar 30;11:638918
pubmed: 33859943
Eur J Cancer. 2017 Apr;75:5-13
pubmed: 28214658
Int J Cancer. 2021 Feb 1;148(3):546-559
pubmed: 32790899
J Clin Oncol. 2011 Jan 1;29(1):25-31
pubmed: 21115856
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
Am J Epidemiol. 2000 Sep 15;152(6):514-27
pubmed: 10997541
Oncogene. 2009 Jul 30;28(30):2745-55
pubmed: 19483720
Science. 2013 Aug 23;341(6148):856-8
pubmed: 23970691
Nat Rev Endocrinol. 2018 Oct;14(10):576-590
pubmed: 30046148
Clin Cancer Res. 2017 Sep 15;23(18):5561-5572
pubmed: 28606920
Front Endocrinol (Lausanne). 2019 May 03;10:266
pubmed: 31130916
Oncol Rep. 2020 Aug;44(2):509-518
pubmed: 32627029
PLoS One. 2015 Oct 07;10(10):e0139112
pubmed: 26444008
Nat Rev Genet. 2014 Sep;15(9):585-98
pubmed: 24981601
J Immunother Cancer. 2020 Sep;8(2):
pubmed: 32958684
Int J Cancer. 2004 Sep 20;111(5):762-71
pubmed: 15252848
J Natl Cancer Inst. 2014 Jun 23;106(7):
pubmed: 24957076
Cancers (Basel). 2020 Jul 02;12(7):
pubmed: 32630675
Nature. 2012 Apr 18;486(7403):346-52
pubmed: 22522925
Ageing Res Rev. 2021 May;67:101268
pubmed: 33556548

Auteurs

Ha-Linh Nguyen (HL)

Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium.

Tatjana Geukens (T)

Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium.

Marion Maetens (M)

Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium.

Samuel Aparicio (S)

Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, BC, Canada.
Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.

Ayse Bassez (A)

Laboratory for Translational Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium.
VIB Center for Cancer Biology, Leuven, Belgium.

Ake Borg (A)

Department of Clinical Sciences, Division of Oncology and Pathology, Lund University, Lund, Sweden.
Lund University Cancer Center Lund, Lund, Sweden.
CREATE Health Strategic Centre for Translational Cancer Research, Lund University, Lund, Sweden.
Department of Clinical Sciences, SCIBLU Genomics, Lund University, Lund, Sweden.

Jane Brock (J)

Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.

Annegien Broeks (A)

Departments of Core Facility, Molecular Pathology and Biobanking, Antoni van Leeuwenhoek, the Netherlands Cancer Institute, Amsterdam, the Netherlands.

Carlos Caldas (C)

Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK.

Fatima Cardoso (F)

Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal.

Maxim De Schepper (M)

Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium.

Mauro Delorenzi (M)

Department of Oncology, University of Lausanne, Epalinges, Switzerland.
SIB Swiss Institute of Bioinformatics, Bioinformatics Core Facility, Lausanne, Switzerland.

Caroline A Drukker (CA)

Department of Surgical Oncology, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.

Annuska M Glas (AM)

Agendia, Amsterdam, the Netherlands.

Andrew R Green (AR)

Nottingham Breast Cancer Research Centre, School of Medicine, University of Nottingham, Nottingham, UK.

Edoardo Isnaldi (E)

Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium.

Jórunn Eyfjörð (J)

BioMedical Center, School of Health Sciences, Faculty of Medicine, University of Iceland, Reykjavík, Iceland.

Hazem Khout (H)

Department of Breast Surgery, Glenfield Hospital, University Hospitals of Leicester NHS Trust, Leicester, UK.

Stian Knappskog (S)

Department of Clinical Science, Faculty of Medicine, University of Bergen, Bergen, Norway.
Department of Oncology, Haukeland University Hospital, Bergen, Norway.

Savitri Krishnamurthy (S)

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Sunil R Lakhani (SR)

UQ Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Herston, QLD, Australia.
Pathology Queensland, The Royal Brisbane and Women's Hospital, Herston, QLD, Australia.

Anita Langerod (A)

Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Ullernchausseen, Oslo, Norway.

John W M Martens (JWM)

Department of Medical Oncology and Cancer Genomics Netherlands, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.

Amy E McCart Reed (AE)

UQ Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Herston, QLD, Australia.

Leigh Murphy (L)

University of Manitoba and Cancer Care Manitoba Research Institute, Winnipeg, MB, Canada.

Stefan Naulaerts (S)

Laboratory of Cell Stress & Immunity, Department of Cellular & Molecular Medicine, KU Leuven, Leuven, Belgium.

Serena Nik-Zainal (S)

Department of Medical Genetics, School of Clinical Medicine, University of Cambridge, Cambridge, UK.
MRC Cancer Unit, School of Clinical Medicine, University of Cambridge, Cambridge, UK.

Ines Nevelsteen (I)

Department of Surgical Oncology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.

Patrick Neven (P)

Department of Gynecological Oncology, University Hospitals Leuven, Leuven, Belgium.

Martine Piccart (M)

Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium.

Coralie Poncet (C)

European Organisation for Research and Treatment of Cancer (EORTC) Headquarters, Brussels, Belgium.

Kevin Punie (K)

Department of General Medical Oncology and Multidisciplinary Breast Unit, Leuven Cancer Institute and University Hospitals Leuven, Leuven, Belgium.

Colin Purdie (C)

Department of Pathology, University of Dundee, NHS Tayside, Dundee, UK.

Emad A Rakha (EA)

Division of Cancer and Stem Cells, School of Medicine, University of Nottingham, Nottingham, UK.
Department of Histopathology, Nottingham University Hospital NHS Trust, City Hospital Campus, Nottingham, UK.

Andrea Richardson (A)

Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Emiel Rutgers (E)

Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.

Anne Vincent-Salomon (A)

Diagnostic and Theranostic Medicine Division, Institut Curie, PSL Research University, Paris, France.

Peter T Simpson (PT)

UQ Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Herston, QLD, Australia.

Marjanka K Schmidt (MK)

Division of Molecular Pathology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.

Christos Sotiriou (C)

Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium.

Paul N Span (PN)

Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.

Kiat Tee Benita Tan (KTB)

Department of General Surgery, Sengkang General Hospital, Singapore, Singapore.
Department of Breast Surgery, Singapore General Hospital, Singapore, Singapore.
Department of Breast Surgery, National Cancer Centre, Singapore, Singapore.

Alastair Thompson (A)

Department of Surgery, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.

Stefania Tommasi (S)

Molecular Diagnostics and Pharmacogenetics Unit, IRCCS Istituto Tumouri "Giovanni Paolo II", Bari, Italy.

Karen Van Baelen (K)

Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium.

Marc Van de Vijver (M)

Department of Pathology, Amsterdam University Medical Centers, Cancer Center Amsterdam, University of Amsterdam, Amsterdam, the Netherlands.

Steven Van Laere (S)

Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Antwerp, Belgium.

Laura Van't Veer (L)

Department of Laboratory Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.

Giuseppe Viale (G)

Division of Pathology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

Alain Viari (A)

Synergie Lyon Cancer, Plateforme de Bio-informatique 'Gilles Thomas', Lyon, France.

Hanne Vos (H)

Department of Surgical Oncology, University Hospitals Leuven, Leuven, Belgium.

Anke T Witteveen (AT)

Agendia, Amsterdam, the Netherlands.

Hans Wildiers (H)

Department of General Medical Oncology and Multidisciplinary Breast Unit, Leuven Cancer Institute and University Hospitals Leuven, Leuven, Belgium.

Giuseppe Floris (G)

Department of Pathology, University Hospitals Leuven, Leuven, Belgium.

Abhishek D Garg (AD)

Laboratory of Cell Stress & Immunity, Department of Cellular & Molecular Medicine, KU Leuven, Leuven, Belgium.

Ann Smeets (A)

Department of Surgical Oncology, University Hospitals Leuven, Leuven, Belgium.

Diether Lambrechts (D)

Laboratory for Translational Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium.
VIB Center for Cancer Biology, Leuven, Belgium.

Elia Biganzoli (E)

Unit of Medical Statistics, Biometry and Epidemiology, Department of Biomedical and Clinical Sciences (DIBIC) "L. Sacco" & DSRC, LITA Vialba campus, Università degli Studi di Milano, Milan, Italy.

François Richard (F)

Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium.

Christine Desmedt (C)

Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium. christine.desmedt@kuleuven.be.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH